Barinthus Biotherapeutics plc (BRNS) 股票分析

公司概述

Barinthus Biotherapeutics plc is a biotechnology enterprise focused on the research, development, and commercialization of immunotherapies and vaccines within the United States and the United Kingdom markets. As a company operating within the healthcare sector specifically under the biotechnology industry, the firm is dedicated to advancing antigen-specific immune tolerance candidates, with its primary asset being VTP-1000 which has progressed into Phase I clinical trials. The organization currently maintains a market capitalization of $22.47 million and employs a workforce of 14 individuals. These valuation and operational metrics indicate that Barinthus operates as a small-cap entity with limited revenue generation, reflecting the typical financial profile of early-stage biotechnology firms that prioritize clinical progression over immediate profitability.

财务健康

The company reports a trailing twelve-month revenue of N/A and recorded a net loss of $-66,428,000 over the same period, while its EBITDA stands at $-55,223,000. The significant gap between the reported revenue (which is unavailable) and the substantial net loss reveals a cost structure heavily weighted toward research and development expenditures rather than commercial sales. Free cash flow for the trailing twelve months is $-28,044,376, which signifies that the company is burning cash to fund its operations and clinical programs. The gross margin is recorded at 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, indicating that the company has not yet achieved positive profitability or cost recovery relative to its revenue base. On the balance sheet, the firm holds $70.46 million in cash against $11.28 million in debt, resulting in a debt-to-equity ratio of 15.19, which suggests a capital structure that relies predominantly on equity financing rather than debt leverage. Despite the high debt-to-equity figure, the current ratio of 7.76 indicates robust short-term liquidity, as the company possesses substantial current assets relative to its current liabilities. The return on equity is -65.0% and the return on assets is -28.1%, metrics that reflect the negative impact of accumulated losses on the book value of the company's equity and total assets.

估值评估

The trailing twelve-month P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -0.48, a figure that implies the market is pricing in a continued period of negative earnings growth or a specific accounting adjustment for future periods. The price-to-book ratio stands at 0.30, indicating that the market is currently valuing the company at significantly less than the accounting book value of its net assets. The price-to-sales ratio is N/A, and the EV/EBITDA multiple is 0.66, suggesting an alternative valuation perspective that places the firm's enterprise value very close to its earnings before interest, taxes, depreciation, and amortization, albeit with negative earnings. Over the past year, the stock has ranged between a 52-week low of $0.51 and a 52-week high of $2.92, trading within a range that highlights significant historical volatility for a small-cap biotech stock. The beta of -0.60 is a notable anomaly that suggests the stock price has historically moved in an inverse relationship to the broader market or specific sector indices, though such a negative beta is rare and specific to this asset's unique trading characteristics.

Growth & Income

Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, meaning there is no historical data available to compare growth rates between the two metrics. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that the firm retains all available capital to reinvest into its research pipeline and clinical development efforts rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's life-cycle stage, where capital preservation and funding of Phase I trials take precedence over income generation for investors. Consequently, the overall growth and income profile of Barinthus Biotherapeutics is characterized by a lack of current income distribution and undefined historical growth rates, positioning the asset purely as a venture-stage investment reliant on future clinical milestones for value creation.